A Review on Novel Approach – Bilayer Tablet Technology

Shila V. Devtalu1, Ashwini E. Patil1, Manoj M. Bari1, Dr. Shashikant D. Barhate1
1Department of Pharmaceutics, Shree Sureshdada Jain Institute of Pharmaceutical Education and Research, Jamner, Jalgaon Dist, Maharashtra, India.
*Corresponding author’s E-mail: shiladevtalu@gmail.com

Accepted on: 03-04-2013; Finalized on: 30-06-2013.

ABSTRACT

In modern era bi-layer tablet is for successful development of immediate and modified drug delivery system for various diseases and disorders. Bi-layer tablets have been developed to achieve modified release of drug. The primary objective of bi-layer tablet is to avoid chemical incompatibilities between APIs by physical separation and to develop different drug release profiles (immediate release and modified release). In bi-layer tablet the immediate release layer act as the loading dose and modified release layer act as the maintenance dose. To produce a good quality bi-layer tablet, the machinery should be constructed as per GMP. Various machineries are available to overcome common bi-layer problems, such as layer separation, insufficient hardness, inaccurate individual weight control, cross contamination between the layers etc. In this review we focus on the different types of press, techniques, how to solve problems of bi-layer tablet, marketed products etc.

Keywords: Approaches, Bi-layer tablet, Marketed products, Press, Techniques, Trouble shooting.

INTRODUCTION

Day-by-day’s various developed and developing countries are moving towards combination therapy for treatment of various diseases and disorders requiring long term therapy such as hypertension and diabetes. The problem of dose dependent side effects is minimized by combination therapies and is advantageous over monotherapy.1-5 From last few years, interest in developing a combination of two or more active pharmaceutical ingredients in a single dosage form has increased in pharmaceutical industry. Bi-layer tablets can be a primary option to avoid chemical incompatibilities between APIs by physical separation.6,7,8 Bi-layer tablet is suitable for sequential release of two drugs in combination, separate two incompatible substances and also for sustained release tablet in which one layer is immediate release as initial dose and second layer is maintenance dose.9,10

Bi-layer tablets are prepared with one layer of drug for immediate release with second layer design to release drug later as second dose or in an extended release or for both immediate release. Bi-layer tablets are tablet, made by compressing two different granulations fed into a die succession, one on top of another, in layers. Each layer comes from a separate feed frame with individual weight control. Rotary tablet press can be set up for two layers. More layers are possible but the design becomes very special. Bi-layer tablets are composed of two layers of granulation compressed together. They have the appearance of a sandwich because the edges of each layer are exposed.5 General concept of bi-layer tablet is shown in figure 1.

However, these drug delivery devices are mechanically complicated to design/manufacture and harder to predict their long term mechanical properties due to the poor mechanical and compression characteristics of the constituent materials in the compacted adjacent layers, elastic mismatch of the layers, insufficient hardness, inaccurate individual mass control, cross contamination between the layers, reduced yield, and their tendency to delaminate at the interface between the adjacent compacted layers during and after the various stages of production downstream of the compaction process.14

Rationale behind formulation of bi-layer tablet6,12

1. Controlling the delivery rate of either single or two different APIs.
2. To separate incompatible API’s with each other, to control the release of one layer by utilizing the functional property of the other layer (such as osmotic property).
3. To adapt the total surface area available for API layer either by sandwiching with one or two
inactive layers in order to achieve swellable/erodible barriers for controlled release.

Applications
1. Bi-layer tablets are mainly used in combination therapy.
2. Bi-layer tablets are used to deliver the loading dose and maintenance dose of the same or different drug.
3. Bi-layer tablets are used for bi-layer floating tablets in which one layer is floating layer another one is immediate release layer of the drug.
4. Bi-layer tablets are used to deliver the two different drugs having different release profile.

GMP-requirements of quality bi-layer tablet
To produce a quality bi-layered tablet, in a validated and GMP way, it is important to select a bi-layer tablet press capable of:
1. Preventing capping and separation of the two individual layers that constitute the bi-layer tablet.
2. Providing sufficient tablet hardness.
3. Preventing cross-contamination between the two layers.
4. Producing a clear visual separation between the two layers.
5. Accurate and individual weight control of the two layers.
6. High yield.

Advantages of bi-layer tablet over the conventional oral solid dosage forms
1. Low cost compared to other dosage forms.
2. Fit for large scale production.
3. Bi-layer tablet is suitable for preventing direct contact of two drugs and thus to maximize the efficacy of combination of two drugs.
4. Expansion of a conventional technology.
5. Separation of incompatible components.
6. Patient compliance is improved leading to improve drug regimen efficiency.
7. Fewer daily doses are required compared to traditional delivery system.
8. Product identification is easy.

Disadvantages of bi-layer tablet
1. Difficult to swallow in case of children and unconscious patients.
2. Add complexity and bi-layer tablet presses are expensive.
3. Insufficient hardness, layer separation, reduced yield.
4. Inaccurate individual layer weight control.
5. Some drugs resist compression into dense compacts, owing to amorphous nature, low density character.

Various techniques of bi-layer tablet
1. Oros * push pull technology

This system consist of mainly two or three layer among which the one or more layer are necessary for the drug and other layer are consist of push layer. The drug layer mainly consists of drug along with two or more different agents. So this drug layer comprise of drug which is in poorly soluble form. There is further addition of suspending agent and osmotic agent. A semi permeable membrane surrounds the tablet core.

2. L-Orostm technology

This system used for the solubility concern Alza developed the L-OROS system where a lipid soft gel product containing drug in a dissolved state is initially manufactured and then coated with a barrier membrane, then osmotic push layer and then a semi permeable membrane, drilled with an exit orifice.

3. DUROS technology

DUROS (Alza Corporation) is based on implant technology, which provides an alternative of a wide range of therapeutic compounds, includes peptides, proteins and other bioactive macromolecules. These implants are miniature titanium cylinders designed to provide continuous osmotically driven delivery of drugs within the body for up to one year.

4. EN SO TROL technology

Solubility enhancement of an order of magnitude or to create optimized dosage form Shire laboratory used an integrated approach to drug delivery focusing on identification and incorporation of the identified enhancer into controlled release technologies.

Compression cycle for bi-layer tablet

Bi-layer tablets are made by compressing two different granulations fed into a die succession, one on top of another, in layers. Each layer comes from a separate feed frame with individual weight control. Rotary tablet press can be set up for two or three layers. More are possible but the design becomes very special. Mechanism of compression of bi-layer tablet is shown in figure 2.

Figure 2: Compression cycle of bi-layer tablet

Various approaches used in bi-layer tablet

A. Floating drug delivery system

They are designed to have a low density and thus float on the gastric contents after administration until the system either disintegrates or the device absorbs fluid to the point where its density is such that it loses buoyancy and can pass more easily from the stomach.
with a wave of motility responsible for gastric emptying. The bi-layer tablet is designed in such way that, one layer gives immediate dosing of the drug which gives faster onset of action while other layer is designed as a floating layer which forms a gastro retentive system. Release pattern of floating bi-layer tablet is shown in figure 3.

Figure 3: Release pattern of bi-layer floating tablet

B. Polymeric bioadhesive system

These are designed to imibe fluid flowing administration such that the outer layer becomes a viscous, tacky material that adheres to the gastric mucosa/mucus layer. This should encourage gastric retention until the adhesive forces are weakened. These are prepared as a one layer with immediate dosing and other layer with bioadhesive property.

C. Swelling system

These are designed to be sufficiently small on administration so as not to make ingestion of the dosage form difficult (e.g., less than approximately 23 mm long and less than 11 mm wide for an oval or capsule-shaped tablet whereas 10-12 mm in diameter for round tablets). On ingestion they rapidly swell or disintegrate or unfold to a size that precludes passage through the pylorus until after drug release has progressed to a required degree. Gradual erosion of the system or its breakdown into smaller particles enables it to leave stomach. The simple bi-layer tablet may contain an immediate release layer with the other layer as extended release or conventional release or both as controlled release layer. Such systems are shown in figure 4 and figure 5.

Figure 4: Bi-layer tablet consist of two controlled release layer

Figure 5: Bi-layer tablet consist of immediate release and controlled release layer

Types of bi-layer tablet press

1. **Single sided tablet press**

   The simplest design is the single sided press with both chambers of the double feeder separation from each other. Each chamber is gravity or fed with different powder, thus producing the two individual layers of the tablets. When the die passes under the feeder, it is first loaded with the first-layer powder followed by the second layer powder. Then the tablet is compressed in one or two steps. Various bi-layer tablet press are enlisted in table no. 1. Single Sided 16 to 23 stations bi-layer tablet press is as shown in figure 6.

1.1 Single Sided 16 to 23 stations (JS) Standard & GMP Heavy Duty Machine

   - Suitable for veterinary, herbal, chemicals, minerals, confectionary, metal.
   - Pharmaceuticals and nutraceuticals
   - R & D/ Pilot scale model
   - Machines with pre-compression
   - PLC & computer interfaced controls
   - 23- Station machine is with B-Tooling

2. **Double sided tablet press**

   A double sided press offers an individual fill station, pre-compression and main compression for each layer. In fact bi-layer tablet will go through four compression stages before being ejected from the press. Most double sided tablet press with automated production control use compression force to monitor and control
tablet weight. ADEPT double sided tablet press is as shown in figure 7.

2.1 ADEPT double sided tablet press

Offers significant technical advantages that permit higher output and increased efficiency in production. Special emphasis has been given on durability while designing so that the machine can be used in a 24/7 production environment. The higher load bearing capacity of Adept tablet press makes it suitable for bigger tablets. The machine also offers flexibility to produce both single-layer and bi-layer tablets on the same platform.

Figure 7: ADEPT Double Sided Tablet Press

3. Bi-layer tablet press with displacement monitoring

Tablet weight control using ‘displacement’ is based on the measurement of thickness variations under constant force and is measured at pre-compression. This measurement is possible when using the so-called ‘pneumatic compensator’. The displacement-tablet weight control principle is fundamentally different from the principle based upon compression force. When measuring displacement, the control system’s sensitivity does not depend on the operating point on the graph (i.e. it does not depend on the tablet weight) but depends on the applied pre compression force. In fact, the lower the pre-compression force, the more sensitive the monitoring/ control system and this is ideal for good interlayer bonding of the bi-layer tablet, as explained above. The Courtoy R292F; "bi-layer" tablet press with ‘displacement monitoring’ is as shown in figure 8.

3.1 The Courtoy R292F; "bi-layer" tablet press with ‘displacement monitoring’

This double-sided tablet press has been specifically designed and developed for the production of quality bi-layer tablets and provides:

- 'Displacement' weight monitoring/control for accurate and independent weight control of the individual layers.
- Low compression force exerted on the first layer to avoid capping and separation of the two individual layers.
- Increased dwell time at pre-compression of both first and second layer to provide sufficient hardness at maximum turret speed.
- Maximum prevention of cross-contamination between the two layers.
- A clear visual separation between the two layers.
- Maximized yield.

Figure 8: Courtoy R292F bi-layer press

Table 1: Bi-layer tablet press available in the market

<table>
<thead>
<tr>
<th>Bi-layer Tablet Press</th>
<th>Make</th>
</tr>
</thead>
<tbody>
<tr>
<td>Expert 1 bi-layer tablet press for R&amp;D</td>
<td>Kambert</td>
</tr>
<tr>
<td>Modul™ P with bi-layer ECM</td>
<td>GEA Courtesy</td>
</tr>
<tr>
<td>XM 12 small scale bi-layer tablet press</td>
<td>Korsch</td>
</tr>
<tr>
<td>OYSTAR Manesty Xpress+ 700 Tablet Press</td>
<td>Thomasnet</td>
</tr>
<tr>
<td>ADEPT double sided tablet press</td>
<td>Adept</td>
</tr>
<tr>
<td>Piccola-bi-layer tablet press</td>
<td>Smtmc</td>
</tr>
<tr>
<td>Double sided bi-layer tablet press</td>
<td>Jaguar</td>
</tr>
<tr>
<td>Bi-layer tablet press</td>
<td>Aayush Techno Pvt. Ltd.</td>
</tr>
<tr>
<td>Double tablet press</td>
<td>Kambert Engineering Ltd.</td>
</tr>
<tr>
<td>Double rotary double layer tablet press</td>
<td>Karnavati Engineering Ltd.</td>
</tr>
</tbody>
</table>

Troubleshooting of processing problems in bi-layer tablet compression

Various problems are arises in the process of compression of bi-layer tablet, these are summarized in table 2.

Evaluation of bi-layer tablet

General Appearance

The general appearance of a tablet, its visual identity and overall “elegance” is essential for consumer acceptance. Includes tablet size, shape, color, presence or absence of an odor, taste, surface texture, physical flaws and consistency and legibility of any identifying marking.
Size and Shape
The size and shape of the tablet can be dimensionally described, monitored and controlled.

Tablet thickness
Tablet thickness is an important characteristic in reproducing appearance and also in counting by using filling equipment. Some filling equipment utilizes the uniform thickness of the tablets as a counting mechanism. Thickness of tablet should be recorded by using digital vernier caliper. It is expressed in mm.

Hardness (Crushing strength)
Hardness indicates the ability of the tablet to withstand mechanical shocks while handling. Hardness of the tablet recorded by Monsanto hardness tester. It is expressed in kg/cm².

Table 2: Troubleshooting of processing problems in bi-layer tablet compression

<table>
<thead>
<tr>
<th>Trouble</th>
<th>Possible cause</th>
<th>Remedies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tablet weight variation</td>
<td>1. Poor flow characteristics of material</td>
<td>a. Wrong setting of hopper.</td>
</tr>
<tr>
<td></td>
<td>3. Material loss or gain after proper die fill</td>
<td>c. Too much recirculation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>a. Press running too fast</td>
</tr>
<tr>
<td></td>
<td></td>
<td>b. wrong feeder paddle speed or shape</td>
</tr>
<tr>
<td></td>
<td></td>
<td>a. Recirculation band leaking</td>
</tr>
<tr>
<td></td>
<td></td>
<td>b. Excessive vacuum or nozzle improperly located</td>
</tr>
<tr>
<td>Product yield</td>
<td>1. Incorrect feeder fit to die table</td>
<td>a. Feeder bases incorrectly set (too high or not level)</td>
</tr>
<tr>
<td></td>
<td>2. Incorrect action on recirculation band</td>
<td>a. Gap between bottom edge and die table</td>
</tr>
<tr>
<td></td>
<td>3. Die table scraper action insufficient</td>
<td>b. Binding in mounting screw</td>
</tr>
<tr>
<td></td>
<td>4. Loss at compression point</td>
<td>c. Too little hold down spring pressure</td>
</tr>
<tr>
<td>Low hardness</td>
<td>1. Factors related to machine</td>
<td>a. Scrapper blade worn or binding</td>
</tr>
<tr>
<td></td>
<td>2. Lubricant level</td>
<td>a. Outboard edge permitting material to escape</td>
</tr>
<tr>
<td></td>
<td></td>
<td>a. Compressing too high in the die</td>
</tr>
<tr>
<td></td>
<td></td>
<td>a. Excessive or misdirected suction on exhaust nozzle</td>
</tr>
<tr>
<td>Capping and lamination</td>
<td>1. Non-optimized formulation</td>
<td>a. Incorporate plastically deforming matrix</td>
</tr>
<tr>
<td></td>
<td>2. High compression force</td>
<td>a. Reduced compression force</td>
</tr>
<tr>
<td></td>
<td>3. Ratio of pre-compression to main compression is insufficient</td>
<td>b. Reduced press speed</td>
</tr>
<tr>
<td></td>
<td>4. Curled or damaged punches</td>
<td>a. Pre-compression force high can be harmful</td>
</tr>
<tr>
<td></td>
<td></td>
<td>b. Use large compression roller diameter</td>
</tr>
<tr>
<td>Picking and sticking</td>
<td>1. Excessive heat generation during compression</td>
<td>a. Tools should be re washed or replaced</td>
</tr>
<tr>
<td></td>
<td>2. Fouling the punch faces</td>
<td></td>
</tr>
<tr>
<td>Separation of two individual layers</td>
<td>1. Insufficient bonding between the two layers during final compression of bi-layer tablet</td>
<td>a. Startup should always be close to optimum conditions</td>
</tr>
<tr>
<td>Mottling</td>
<td>1. Improper setting of both feed frame</td>
<td>a. First layer should be compressed at a low compression force so that this layer can still interact with second layer during final compression of the tablet</td>
</tr>
<tr>
<td></td>
<td>2. Due to weak suction</td>
<td></td>
</tr>
</tbody>
</table>

Friability
The ability of the tablet to withstand abrasion in packaging, handling and shipping. Friability is determined by the use of the Roche friabilitator. A number of tablets are weighed and placed in the apparatus where they are exposed to rolling and repeated shocks as they fall 6 inches in each turn within the apparatus. After four minutes of this treatment or 100 revolutions, the tablets are weighed and the weight compared with the initial weight. The loss due to abrasion is a measure of the tablet friability. The value is expressed as a percentage. A maximum weight loss of not more than 1% of the weight of the tablets being tested during the friability test is considered generally acceptable and any broken or smashed tablets are not picked up. Friability is expressed in percentage as:

\[
\% \text{Friability} = \frac{1}{n} \times \left( \frac{\text{Loss in weight}}{\text{Initial weight}} \right) \times 100
\]

Drug content and release
To evaluate tablets potential for efficacy, the amount of drug per tablet needs to be monitored from tablet to tablet and batch to batch, and a measure of the tablet’s ability to release the drug needs to be ascertained.
Weight variation

Twenty tablets are selected randomly from each batch and weighed individually to check weight variation. Calculate average weight and comparing the individual tablet weights the average. The tablet meet the USP test if no more than 2 tablets are outside the percentage limit and if no tablet differs by more than 2 times the percentage limit. A little variation is allowed in weight of a tablet according to U. S. Pharmacopoeia. The following percentage deviation shown in table no. 3 in weight variation is allowed.

<table>
<thead>
<tr>
<th>Average weight of tablet</th>
<th>Percentage deviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>130 mg or less</td>
<td>±10</td>
</tr>
<tr>
<td>&gt;130 mg and &lt;324 mg</td>
<td>±7.5</td>
</tr>
<tr>
<td>324 mg or more</td>
<td>±5</td>
</tr>
</tbody>
</table>

In-vitro dissolution study

Dissolution study is done in simulated gastric and intestinal fluids to assess their ability in providing the desired controlled drug delivery. In- vitro drug release studies are carried out using USP dissolution test apparatus at 37°C temperature at specific RPM or as mentioned in monograph.

Marketed bi-layer tablets

Various researcher works on bi-layer tablet, which are shown in table no. 4. Commercially available bi-layer tablets are enlisted in table 5.

CONCLUSION

Bi-layer tablet is suitable for sequential release of two drugs in combination, and also for sustained release tablet in which one layer is immediate release as an initial dose and second layer is maintenance dose. By using bi-layer tablet technology we can administer incompatible drugs in combination as well as same drug with different release rate. This technology avoids frequent administration of dosage form. Now a day such technology is used for administration of drugs like anti-diabetic, anti-hypertensive, anti-inflammatory, anti-pyretic, anti-asthmatic to the patients. Conventional solid oral dosage forms are a traditional, but bi-layer tablet is a novel approach. This novel approach requires new machinery for manufacturing. This article explains different types of presses used to produce bi-layer tablet ranging from simple single sided machines to highly sophisticated machines. For good quality bi-layer tablet the machines should be inherently built as per GMP. This technique is cost effective, safe and reproducible.

Table 3: Weight variation parameters

<table>
<thead>
<tr>
<th>Average weight of tablet</th>
<th>Percentage deviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>130 mg or less</td>
<td>±10</td>
</tr>
<tr>
<td>&gt;130 mg and &lt;324 mg</td>
<td>±7.5</td>
</tr>
<tr>
<td>324 mg or more</td>
<td>±5</td>
</tr>
</tbody>
</table>

Table 4: Previous study done on bi-layer tablet

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Super disintegrant used in Immediate release layer</th>
<th>Polymer used in Sustained release layer</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glimepride</td>
<td>Sodium starch glycolate</td>
<td>HPMC K4M, sodium carboxymethyl cellulose</td>
<td>19</td>
</tr>
<tr>
<td>Paracetamol</td>
<td>Microparticles by ethylcellulose</td>
<td>Microparticles by ethylcellulose</td>
<td>24</td>
</tr>
<tr>
<td>Tramadol HCL</td>
<td>Sodium starch glycolate as superdisintegrant</td>
<td>Sodium starch glycolate as superdisintegrant</td>
<td>25</td>
</tr>
<tr>
<td>Valsartan</td>
<td>Metformin HCL</td>
<td>HPMC K100M, sodium CMC, PVP K90</td>
<td>26</td>
</tr>
<tr>
<td>Glipizide</td>
<td>Glipizide</td>
<td>HPMC, xanthan gum, guar gum, karaya gum</td>
<td>27</td>
</tr>
<tr>
<td>Zolpidem tartrate</td>
<td>Sodium crosscarmellose</td>
<td>HPMC K100M</td>
<td>28</td>
</tr>
<tr>
<td>Ranitidine</td>
<td>Ranitidine</td>
<td>Carbopol, HPMC</td>
<td>17</td>
</tr>
</tbody>
</table>

Table 5: Marketed bi-layer tablets

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Active Pharmaceutical Ingredients (API)</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pioglu</td>
<td>Pioglitazone, Metformin hydrochloride</td>
<td>Emcure Pharmaceutical Ltd.</td>
</tr>
<tr>
<td>Xilla M- Forte</td>
<td>Glimepride, Metformin hydrochloride</td>
<td>Emcure Pharmaceutical Ltd.</td>
</tr>
<tr>
<td>Gluconorm</td>
<td>Glimepride, Metformin hydrochloride</td>
<td>Lupin Pharmaceuticals</td>
</tr>
<tr>
<td>Volise-M</td>
<td>Voglibose, Metformin hydrochloride</td>
<td>Ranbaxy Laboratories Ltd.</td>
</tr>
<tr>
<td>Glimeto- MP</td>
<td>Glimepride, Pioglitazone</td>
<td>RPG Life Sciences Ltd.</td>
</tr>
<tr>
<td>Istamet</td>
<td>Sitagliptin, Metformin hydrochloride</td>
<td>Ranbaxy Laboratories Ltd.</td>
</tr>
<tr>
<td>Glyrep</td>
<td>Glyclizide, Metformin hydrochloride</td>
<td>Emcure Pharmaceutical Ltd.</td>
</tr>
<tr>
<td>Unistar</td>
<td>Rosuvastatin, Aspirin</td>
<td>Unichem Laboratories Ltd.</td>
</tr>
</tbody>
</table>
REFERENCES


32. www.pharmatechnologyindex.com/viewas.asp?id=50013105582100076


34. www.asianmedical.com

35. www.tradekey.com

36. www.paxhealthcare.com

37. www.rxlist.com

Source of Support: Nil, Conflict of Interest: None.